​Overview and data in biofilm sectors: why targeting biofilms is necessary, Dustin Williams
Impact of biofilms in orthopaedics as they relate to regulatory requirements and needs to be met, David Armbruster, MS, MSE, R&D Group Manager, DePuy Synthes
Clinical problems of biofilm implant-related infection and methods/need to target biofilms in patients, Javad Parvizi, MD, Professor of Orthopaedic Surgery, Rothman Institute at Thomas Jefferson University Hospital
Impact of biofilms in catheter systems and regulatory considerations,
Bryan Haymond, MBA, Product Manager, Bard Access Systems
Potential benefits of targeting biofilms in wound-related and other tissue infections, Garth James, PhD, Associate Research Professor, Center for Biofilm Engineering, Montana State University
Biofilms, prevalence and problems related to injured soldiers and military healthcare facilities, COL Clinton K. Murray, MD, FACP, FIDSA, Colonel, US Army
FDA insight into the biofilm problem and regulatory management strategy for medical devices, K. Scott Phillips, PhD, Biofilms Research Group Leader, The US FDA and CDR US Public Health Service
Benefits of standardizing approaches to assessing antimicrobial efficacies against biofilms for industrial applications, Darla Goeres, PhD, Associate Research Professor, Chemical & Biological Engineering, Standards Biofilm Methods Laboratory, Center for Biofilm Engineering, Montana State University
EPA insight in the biofilm problem and regulatory management strategy for industrial sectors, Steve Tomasino, PhD, Senior Scientist, Environmental Protection Agency